Founded in December 2017,RaysightMed is a leading enterprise in cardiovascular functional diagnosis. It is committed to providing a precise diagnosis and treatment platform for cardiovascular and cerebrovascular AI+surgical robots for clinical use. It has completed five rounds of financing led by investment institutions such as Guoke Jiahe, Huachuang, Jingwei, Tencent, and Guotou Investment.
As a national high-tech enterprise and specialized new enterprise, the company has launched a non-invasive functional diagnosis system RuiXin FFR, a preoperative surgical plan planning system RuiXin Planner, an intraoperative one-stop macro FFR+micro IMR evaluation system AngioQFA, and a fully automatic AI vascular intervention surgical robot system based on artificial intelligence, computational fluid dynamics, robotics, and connected sensor chip technology.
The company holds 11 NMPA registration certificates and one EU CE mark, has applied for and authorized more than 200 patents, collaborates with more than 800 clinical partner hospitals, and has participated in on more than 50 product research projects. To date, its products have been used safely in over 200,000 patients.
